« Previous
Next »
Titles
- REMS: FDA's application of statutory factors in determining when a REMS is necessary1
- Raising the bar: how California can use purchasing power and oversight to improve quality in Medi-Cal managed care1
- Ready or not: protecting the public's health from diseases, disasters and bioterrorism : 20191
- Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 20151
- Recent Medicaid/CHIP enrollment declines and barriers to maintaining coverage1
- Recommendation followup: vulnerabilities continue to exist in the HHS small business innovation research program1
- Recommendations for reducing the risk of transfusion-transmitted babesiosis1
- Recommended content and format of non-clinical bench performance testing information in premarket submissions: guidance for industry and Food and Drug Administration staff1
- Reducing educational debt among underrepresented physicians and dentists1
- Reducing wasteful spending in employers' pharmacy benefit plans1
- Refuse to accept policy for 510(k)s: guidance for industry and Food and Drug Administration staff1
- Registered apprenticeships: a viable career path for the early childhood workforce1
- Requests for feedback and meetings for medical device submissions: the Q-Submission Program : guidance for industry and Food and Drug Administration staff1
- Risk evaluation and mitigation strategies: modifications and revisions1
- Risk reduction and management of delirium: a national clinical guideline1
- Rx price watch report: price growth for brand name and specialty drugs more than offset price decrease for generic drugs1
- Rx price watch report: specialty prescription drug prices continue to climb1